{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "KNSA",
  "name": "Kiniksa Pharmaceuticals International, plc",
  "url": "https://frontierpicks.com/dossiers/KNSA/",
  "json_url": "https://frontierpicks.com/dossiers/KNSA.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "Post-print commercial re-rating still working but no longer fed by new information: the 2026-07-28 FY26 ARCALYST guidance raise to $980–995M and the 07-29/07-30 target ladder are three weeks old, the 08-12 Canaccord fireside produced no new number, and price closed $79.03 on 2026-08-21, 2.3% under the $80.92 high with RSI 66.4. Next dated binary is the Q3 print, est. ~2026-10-27.",
  "invalidation_trigger": "A weekly close below $70 (unwinds the 2026-07-28 guidance-raise gap and puts price back inside the pre-raise range); secondary break if the Q3 print, est. ~2026-10-27, reiterates or narrows rather than lifts the $980–995M FY26 ARCALYST guidance.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "rare-disease-gene-therapy",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Ireland-domiciled plc: Class A ordinary shares trade on Nasdaq; Class A1/B/B1 classes exist and are not publicly traded.",
    "A 2026-05-21 deed of waiver caps Baker Bros. Conversions at 49.9% of the company's voting rights.",
    "Guidance is issued at the ARCALYST net-product-revenue level, not total revenue — compare like for like.",
    "Effectively a one-product company: management guides no second commercial product before the 2028/2029 timeframe.",
    "Q3 2026 earnings has not been date-confirmed by the company; late-October references are estimates from prior-year cadence."
  ],
  "body_markdown": "\n> # KNSA — Kiniksa Pharmaceuticals International, plc\n\n## Current Thesis\nThe leg being bought is a single-product commercial re-rating with a hard number attached to it on 2026-07-28: ARCALYST (rilonacept, recurrent pericarditis) Q2 net product revenue of $243.6M against $225.457M consensus, EPS $0.30 versus $0.27, and FY26 ARCALYST guidance lifted to $980–995M from $930–945M — $50M at both ends against a street figure of $940.106M. That session carried the shares more than 20% higher (Benzinga movers list, 2026-07-28) and five houses re-marked targets inside 48 hours.\n\nWhat has changed in the two weeks since: price has continued higher without new information. The 2026-08-07 close was $76.06; the 2026-08-21 close was $79.03, which is 2.3% under the $80.92 52-week high, with RSI(14) at 66.4 versus 69.2 a fortnight earlier and a three-month price change of +48.4%. The only company communication in that window was a conference-participation release (2026-08-07) and the fireside chat itself at the Canaccord Genuity 46th Annual Growth Conference on 2026-08-12, 9:00 a.m. ET. No guidance revision followed it. No new sell-side target has printed in the last 14 days; aggregators show 8 analysts at a $98 average target as of 2026-08-18, i.e. the ladder built on 2026-07-29/07-30 is still the ladder.\n\nThe narrative is **maturing**. The dates: the re-rating headline is 25 days old (2026-07-28), the target cluster is 23 days old (JP Morgan $107, Citi $100 from $60, Wedbush $99, Canaccord $98 on 2026-07-29; Goldman Sachs $90 on 2026-07-30), the one dated appearance in the window came and went on 2026-08-12 without a new number, and price is still working — higher into a lower RSI reading. That is a known story with moderating headline flow, which is the definition the site uses for maturing rather than accelerating.\n\n## Bull Case\n- Q2 2026 ARCALYST net product revenue $243.6M, approximately 55% YoY growth, with net income $25.4M and diluted EPS $0.30 (Q2 2026 results release, 2026-07-28). The franchise is profitable, not burn-funded.\n- The 2026-07-28 raise took the FY26 ARCALYST floor ($980M) above the prior consensus point estimate of $940.106M — the low end of new guidance cleared the old street number.\n\n- $525.9M in cash, equivalents and short-term investments with no debt, and a stated expectation of remaining cash-flow positive on an annual basis (Q2 2026 release, 2026-07-28). Equity issuance is not the standing overhang it is across most mid-cap biotech.\n- Franchise extension has clinical support: interim Phase 2/3 data for KPL-387 at 300 mg subcutaneous monthly showed a median time to treatment response of 4.0 days (3.0, 6.0); the pivotal Phase 3 PASTORALE trial is enrolling and dosing; FDA granted Orphan Drug Designation in October 2025; the company frames availability in a 2028/2029 timeframe (Q2 2026 release).\n- KPL-1161, targeting quarterly dosing intervals, is guided to enter Phase 1 by year-end 2026 (Q2 2026 release); at least one third-party event calendar carries a ~2026-09-01 start marker, which the company has not confirmed as a date.\n\n## Bear Case\n- Revenue concentration is close to total: one product, one indication, and by the company's own timeline no second commercial product before 2028/2029. A payer, pricing or supply event lands undiluted.\n- The pipeline has already failed once in public — abiprubart in Sjögren's disease was discontinued in the 2025-02-25 corporate strategy update, with strategic alternatives to be explored. That optionality was removed rather than resolved by a readout.\n- The July move priced a raise cadence, not a level. FY26 is now anchored at $980–995M; a Q3 print that leaves the range untouched removes the mechanism that produced the gap even while revenue grows.\n- Targets set immediately after a 20%+ session become a downgrade surface. Goldman Sachs was at $75 on 2026-07-23 and went to $90 on 2026-07-30; Wedbush was at $72 on 2026-06-29 and went to $99; Citi moved $60 to $100. The sell-side re-marked behind the move, and the $98 8-analyst average as of 2026-08-18 is now the reference every valuation note argues against.\n- Insider supply is visible into the strength: StockTitan's filings feed shows a Form 144 for 3,673 Class A shares filed 2026-07-29 and a director (Cole G. Bradley) sale of 3,673 shares at $81.43, plus a Form 4 dated 2026-08-21 recording a director gifting 2,600 shares to a donor-advised fund.\n\n## Setup & Price Structure\nThe structure is a post-gap base that has resolved upward rather than filled. The 2026-07-28 guidance-raise session created the gap; the 2026-08-07 close of $76.06 marked the mid-August consolidation area; the 2026-08-21 close of $79.03 sits 2.3% beneath the $80.92 52-week high. RSI(14) at 66.4 is below the 69.2 reading of two weeks ago despite the higher price — momentum is not expanding with price, which is the observable, not a forecast.\n\nCrowding evidence, stated as observables rather than a verdict: a three-month price change of +48.4%; price within 2.3% of the 52-week high; an 8-analyst average target of $98 struck almost entirely on 2026-07-29/07-30 with nothing new in the following three weeks; a Form 144 filed the day after the print and a director sale reported at $81.43; a further director share transfer filed 2026-08-21. Against that, there is no imminent earnings date inside the window and no announced offering.\n\nThe level that matters structurally is the top of the pre-gap range. A weekly close below $70 would put the shares back inside the price zone that existed before the 2026-07-28 raise, which is the arithmetic the whole leg rests on. The $76 area is where August trade congregated and is the first shelf beneath current price.\n\n## Catalyst Calendar (next 30 days)\n\n- **~2026-09-01 (est., unconfirmed)** — KPL-1161 Phase 1 initiation marker carried on a third-party event calendar. Company guidance is \"by year-end 2026\", so a September start is not a company-set date and should not be graded as one.\n- **~2026-10-27 (est.)** — Q3 2026 results. The first reported quarter against the raised $980–995M FY26 ARCALYST range; no date has been confirmed by the company. This sits outside the 30-day window.\n- **2026-12-31 (est., \"by year-end 2026\")** — KPL-1161 Phase 1 start, per the Q2 2026 release.\n\nThrough roughly 2026-09-21 there is no company-confirmed dated event. Anything that moves the name in that stretch is flow, a sell-side action, or a filing.\n\n## Elapsed catalysts\n\n- **2026-08-12 (elapsed)** — Canaccord Genuity 46th Annual Growth Conference fireside chat, 9:00 a.m. ET, announced 2026-08-07. Held; no guidance revision or new disclosure followed it in the public record through 2026-08-21. *(passed 5d ago)*\n\n## What Would Change Our Mind\nThe structural break is the loss of the pre-gap range top: if the shares unwind the 2026-07-28 guidance-raise advance, the thesis's only hard evidence has been rejected by price. Concretely, a weekly close below $70 marks that, and it would matter more if it happened with no adverse company news, because that would say the buyer of the raise has left rather than been scared out.\n\nThe second break is the cadence, not the level. Q3 (est. ~2026-10-27) reiterating $980–995M — or narrowing to the lower half — removes the raise mechanism that produced the July gap; a print that lifts the range again re-arms it. A third: any of the 2026-07-29/07-30 revisers cutting a target or rating on valuation, since the $98 average as of 2026-08-18 was set behind the move and has had three weeks with nothing added to it.\n\nWhat would raise conviction instead: a Q3 raise, a PASTORALE enrolment-completion disclosure, or a company-confirmed Phase 1 start for KPL-1161 with a protocol date attached.\n\n## Correlation Notes\n- Idiosyncratic first: the 2026-07-28 move was a company revenue print, and the name's dominant driver since is its own filings and target ladder, not sector beta.\n- Small/mid-cap biotech beta still applies to the drawdown case — a broad XBI-type risk-off episode would compress a name trading 2.3% under its 52-week high after a +48.4% three-month run, independent of ARCALYST scripts.\n- No revenue diversification means no internal hedge: with one commercial product, US payer and Medicare Part D policy headlines transmit to the whole revenue line at once, unlike multi-product peers.\n- The share-class structure is a supply channel separate from price: Class A trades on Nasdaq while Class A1/B/B1 do not, and a 2026-05-21 deed of waiver caps Baker Bros. Conversions at 49.9% of voting rights — conversions add Class A float without an offering.",
  "first_seen": "2026-07-29",
  "last_analyzed": "2026-08-22T09:23:24+00:00",
  "last_synthesized": "2026-08-22",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}